JP2021510677A5 - - Google Patents

Download PDF

Info

Publication number
JP2021510677A5
JP2021510677A5 JP2020534949A JP2020534949A JP2021510677A5 JP 2021510677 A5 JP2021510677 A5 JP 2021510677A5 JP 2020534949 A JP2020534949 A JP 2020534949A JP 2020534949 A JP2020534949 A JP 2020534949A JP 2021510677 A5 JP2021510677 A5 JP 2021510677A5
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
pharmaceutical composition
composition according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020534949A
Other languages
English (en)
Japanese (ja)
Other versions
JP7364154B2 (ja
JP2021510677A (ja
Filing date
Publication date
Priority claimed from GBGB1800733.6A external-priority patent/GB201800733D0/en
Application filed filed Critical
Publication of JP2021510677A publication Critical patent/JP2021510677A/ja
Publication of JP2021510677A5 publication Critical patent/JP2021510677A5/ja
Application granted granted Critical
Publication of JP7364154B2 publication Critical patent/JP7364154B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020534949A 2018-01-17 2019-01-16 がんを治療するための選択的parp1阻害剤 Active JP7364154B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1800733.6A GB201800733D0 (en) 2018-01-17 2018-01-17 Cancer
GB1800733.6 2018-01-17
PCT/GB2019/050110 WO2019141979A1 (en) 2018-01-17 2019-01-16 Selective parp1 inhibitors to treat cancer

Publications (3)

Publication Number Publication Date
JP2021510677A JP2021510677A (ja) 2021-04-30
JP2021510677A5 true JP2021510677A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7364154B2 JP7364154B2 (ja) 2023-10-18

Family

ID=61256175

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534949A Active JP7364154B2 (ja) 2018-01-17 2019-01-16 がんを治療するための選択的parp1阻害剤

Country Status (7)

Country Link
US (1) US20210052632A1 (cg-RX-API-DMAC7.html)
EP (1) EP3740238A1 (cg-RX-API-DMAC7.html)
JP (1) JP7364154B2 (cg-RX-API-DMAC7.html)
CN (1) CN111629757A (cg-RX-API-DMAC7.html)
CA (1) CA3087652A1 (cg-RX-API-DMAC7.html)
GB (1) GB201800733D0 (cg-RX-API-DMAC7.html)
WO (1) WO2019141979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer
AU2022334408A1 (en) * 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
JP2025508714A (ja) * 2022-02-16 2025-04-10 デューク ストリート バイオ リミテッド 医薬化合物
KR20250023494A (ko) * 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
CN116397031A (zh) * 2023-04-06 2023-07-07 重庆医科大学 Prdx1-uhrf2-parp1信号通路在制备治疗肝癌的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
US20110190390A1 (en) * 2010-01-05 2011-08-04 Nicole Renee Murray Methods and materials for treating pancreatic cancer
EP3052655B1 (en) * 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
MX393974B (es) * 2016-05-03 2025-03-24 Galera Labs Llc Terapia de combinacion para tratamiento de cancer.
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer

Similar Documents

Publication Publication Date Title
Liu et al. NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression
Lazăr et al. New advances in targeted gastric cancer treatment
Sorbye et al. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer
US20220306688A1 (en) KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto
Jensen et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
Voutsadakis Immune blockade inhibition in breast cancer
JP2023093603A (ja) 癌を治療するための併用療法
ES2986019T3 (es) Tratamientos contra el cáncer que usan combinaciones de inhibidores de ERK y MEK de tipo 2
JP2016514689A5 (cg-RX-API-DMAC7.html)
JP2016526540A5 (cg-RX-API-DMAC7.html)
JP2019515670A5 (cg-RX-API-DMAC7.html)
Molina et al. A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621
RU2016141385A (ru) Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
JP2023022190A (ja) 癌治療
JP2019533651A5 (cg-RX-API-DMAC7.html)
Jalal et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
US20240299392A1 (en) Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
Ahn et al. Synthesis of diethylamino-curcumin mimics with substituted triazolyl groups and their sensitization effect of TRAIL against brain cancer cells
CA3201519A1 (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
JP2015107918A (ja) 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
CN111867598A (zh) 肿瘤免疫赋活剂
Ooi et al. RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update
EP3310746A1 (en) New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol
Dearnaley et al. Escalated-dose Conformai radiotherapy for localised prostate cancer: long-term overall survival results from the MRC RT01 randomised controlled trial